MX2018013003A - Oligonucleotidos para tratar una enfermedad ocular. - Google Patents
Oligonucleotidos para tratar una enfermedad ocular.Info
- Publication number
- MX2018013003A MX2018013003A MX2018013003A MX2018013003A MX2018013003A MX 2018013003 A MX2018013003 A MX 2018013003A MX 2018013003 A MX2018013003 A MX 2018013003A MX 2018013003 A MX2018013003 A MX 2018013003A MX 2018013003 A MX2018013003 A MX 2018013003A
- Authority
- MX
- Mexico
- Prior art keywords
- oligonucleotides
- eye disease
- treat eye
- relates
- exon
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/333—Modified A
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La invención se refiere a los campos de la medicina y la inmunología. En particular, se refiere a oligonucleótidos antisentido novedosos que se pueden usar en el tratamiento, prevención o retraso del síndrome de Usher de tipo II y/o la degeneración de la retina no sindrómica asociada con USH2A, especialmente mediante el salto de un pseudoexón (PE40) entre los exones 40 y 41 del gen USH2A humano.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201607141 | 2016-04-25 | ||
PCT/EP2017/059830 WO2017186739A1 (en) | 2016-04-25 | 2017-04-25 | Oligonucleotides to treat eye disease |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018013003A true MX2018013003A (es) | 2019-01-28 |
Family
ID=58672573
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018013003A MX2018013003A (es) | 2016-04-25 | 2017-04-25 | Oligonucleotidos para tratar una enfermedad ocular. |
Country Status (15)
Country | Link |
---|---|
US (3) | US10617707B2 (es) |
EP (1) | EP3448999B1 (es) |
JP (1) | JP7043082B2 (es) |
KR (1) | KR102368920B1 (es) |
CN (1) | CN109072239A (es) |
AU (1) | AU2017257292A1 (es) |
CA (1) | CA3021899A1 (es) |
DK (1) | DK3448999T3 (es) |
EA (1) | EA201892431A1 (es) |
ES (1) | ES2801823T3 (es) |
IL (1) | IL262199B (es) |
MX (1) | MX2018013003A (es) |
PL (1) | PL3448999T3 (es) |
WO (1) | WO2017186739A1 (es) |
ZA (1) | ZA201806628B (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7043082B2 (ja) | 2016-04-25 | 2022-03-29 | プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ | 眼疾患を処置するオリゴヌクレオチド |
JP7402163B2 (ja) | 2017-12-21 | 2023-12-20 | クリスパー セラピューティクス アーゲー | 2a型アッシャー症候群の処置のための材料および方法 |
EP3728595A1 (en) | 2017-12-21 | 2020-10-28 | CRISPR Therapeutics AG | Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp) |
AU2020215232A1 (en) | 2019-01-28 | 2021-08-26 | Proqr Therapeutics Ii B.V. | RNA-editing oligonucleotides for the treatment of usher syndrome |
EA202192233A1 (ru) * | 2019-02-12 | 2021-11-11 | Университа' Дельи Студи Ди Тренто | МОЛЕКУЛЫ ГИДОВОЙ РНК Cas12a И ИХ ПРИМЕНЕНИЕ |
US20220177894A1 (en) | 2019-04-02 | 2022-06-09 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for immunotherapy |
BR112021020608A8 (pt) | 2019-04-15 | 2023-03-21 | Univ Beijing | Rna recrutador de desaminase, construção, método para editar um rna alvo em uma célula hospedeira, e, construção, composição, célula, biblioteca ou kit |
AU2020259856A1 (en) | 2019-04-18 | 2021-11-18 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of usher syndrome |
WO2020254249A1 (en) | 2019-06-21 | 2020-12-24 | Proqr Therapeutics Ii B.V. | Delivery of nucleic acids for the treatment of auditory disorders |
PE20220300A1 (es) | 2019-07-12 | 2022-03-09 | Univ Beijing | Edicion de acido ribonucleico (arn) dirigido aprovechando la adenosina desaminasa que actua sobre acido ribonucleico endogeno (adar) utilizando acidos ribonucleicos (arn) modificados geneticamente |
AU2020321466A1 (en) | 2019-07-26 | 2022-02-17 | Proqr Therapeutics Ii B.V. | Ophthalmic compositions comprising viscosifying polymers and nucleic acids |
CA3158528A1 (en) | 2019-12-23 | 2021-07-01 | Jim SWILDENS | Antisense oligonucleotides for nucleotide deamination in the treatment of stargardt disease |
KR20220118512A (ko) * | 2019-12-30 | 2022-08-25 | 에디진 테라퓨틱스 (베이징) 인크. | 어셔 증후군의 치료 방법 및 그것의 조성물 |
CN113122577A (zh) * | 2019-12-30 | 2021-07-16 | 博雅辑因(北京)生物科技有限公司 | 一种治疗Usher综合征的方法和其组合物 |
WO2021175904A1 (en) | 2020-03-04 | 2021-09-10 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for use in the treatment of usher syndrome |
US20240141340A1 (en) | 2021-03-05 | 2024-05-02 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for use in the treatment of corneal dystrophies |
TR2022001648A2 (tr) * | 2022-02-09 | 2022-02-21 | T C Ueskuedar Ueniversitesi | Ush2a kaynaklı retinitis pigmentosa hastalığının genetik tedavisi için ekzon 13 atlama işlevi gören kseno nükleik asit antisens-oligonükleotit (xna-aso) dizileri. |
WO2023152371A1 (en) | 2022-02-14 | 2023-08-17 | Proqr Therapeutics Ii B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
WO2024074668A1 (en) * | 2022-10-06 | 2024-04-11 | Stichting Radboud Universitair Medisch Centrum | Antisense oligonucleotides for treatment of usher 2a. exons 30-31 |
WO2024074670A1 (en) * | 2022-10-06 | 2024-04-11 | Stichting Radboud Universitair Medisch Centrum | Antisense oligonucleotides for treatment of usher 2a. exon 68 |
WO2024078345A1 (zh) * | 2022-10-11 | 2024-04-18 | 广州瑞风生物科技有限公司 | snRNA核酸分子及其应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2386540A1 (en) | 1999-10-04 | 2001-04-12 | University Of Medicine And Dentistry Of New Jersey | Novel carbamates and ureas |
EP1191097A1 (en) | 2000-09-21 | 2002-03-27 | Leids Universitair Medisch Centrum | Induction of exon skipping in eukaryotic cells |
US20100196889A1 (en) | 2006-11-13 | 2010-08-05 | Bankaitis-Davis Danute M | Gene Expression Profiling for Identification, Monitoring and Treatment of Colorectal Cancer |
US8093000B2 (en) | 2008-05-09 | 2012-01-10 | The Regents Of The University Of California | Methods for predicting and treating tumors resistant to drug, immunotherapy, and radiation |
US20110070582A1 (en) | 2008-11-03 | 2011-03-24 | Source Precision Medicine, Inc. d/b/d Source MDX | Gene Expression Profiling for Predicting the Response to Immunotherapy and/or the Survivability of Melanoma Subjects |
PT2425814E (pt) | 2010-09-03 | 2013-09-02 | Novagali Pharma Sa | Emulsão de tipo água em óleo para tratamento de uma doença ocular |
US10131910B2 (en) * | 2014-07-10 | 2018-11-20 | Stichting Katholieke Universiteit | Antisense oligonucleotides for the treatment of Usher syndrome type 2 |
US9927034B2 (en) | 2015-08-25 | 2018-03-27 | Mueller International, Llc | Valve seat stiffener |
US10760076B2 (en) | 2015-10-05 | 2020-09-01 | Proqr Therapeutics Ii B.V. | Use of single-stranded antisense oligonucleotide in prevention or treatment of genetic diseases involving a trinucleotide repeat expansion |
JP7043082B2 (ja) | 2016-04-25 | 2022-03-29 | プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ | 眼疾患を処置するオリゴヌクレオチド |
-
2017
- 2017-04-25 JP JP2019506546A patent/JP7043082B2/ja active Active
- 2017-04-25 US US16/096,038 patent/US10617707B2/en active Active
- 2017-04-25 AU AU2017257292A patent/AU2017257292A1/en not_active Abandoned
- 2017-04-25 MX MX2018013003A patent/MX2018013003A/es unknown
- 2017-04-25 CA CA3021899A patent/CA3021899A1/en active Pending
- 2017-04-25 DK DK17721984.7T patent/DK3448999T3/da active
- 2017-04-25 CN CN201780025611.3A patent/CN109072239A/zh active Pending
- 2017-04-25 ES ES17721984T patent/ES2801823T3/es active Active
- 2017-04-25 EA EA201892431A patent/EA201892431A1/ru unknown
- 2017-04-25 WO PCT/EP2017/059830 patent/WO2017186739A1/en active Application Filing
- 2017-04-25 KR KR1020187031243A patent/KR102368920B1/ko active IP Right Grant
- 2017-04-25 EP EP17721984.7A patent/EP3448999B1/en active Active
- 2017-04-25 PL PL17721984T patent/PL3448999T3/pl unknown
-
2018
- 2018-10-05 ZA ZA2018/06628A patent/ZA201806628B/en unknown
- 2018-10-08 IL IL262199A patent/IL262199B/en unknown
-
2020
- 2020-03-06 US US16/811,848 patent/US11123360B2/en active Active
-
2021
- 2021-09-15 US US17/475,795 patent/US20210401871A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20180134931A (ko) | 2018-12-19 |
CA3021899A1 (en) | 2017-11-02 |
IL262199A (en) | 2018-12-31 |
US10617707B2 (en) | 2020-04-14 |
CN109072239A (zh) | 2018-12-21 |
PL3448999T3 (pl) | 2020-11-30 |
US20190381089A1 (en) | 2019-12-19 |
JP2019515688A (ja) | 2019-06-13 |
DK3448999T3 (da) | 2020-06-08 |
US20200237802A1 (en) | 2020-07-30 |
WO2017186739A1 (en) | 2017-11-02 |
ZA201806628B (en) | 2019-07-31 |
IL262199B (en) | 2022-03-01 |
EP3448999B1 (en) | 2020-05-13 |
EP3448999A1 (en) | 2019-03-06 |
US11123360B2 (en) | 2021-09-21 |
KR102368920B1 (ko) | 2022-02-28 |
EA201892431A1 (ru) | 2019-04-30 |
US20210401871A1 (en) | 2021-12-30 |
JP7043082B2 (ja) | 2022-03-29 |
ES2801823T3 (es) | 2021-01-14 |
AU2017257292A1 (en) | 2018-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018013003A (es) | Oligonucleotidos para tratar una enfermedad ocular. | |
MX2019003361A (es) | Oligonucleotidos antisentido para el tratamiento de enfermedad ocular. | |
IL277648A (en) | Medical microbiota for the treatment and/or prevention of food allergy | |
SV2018005614A (es) | Inhibidores peptidicos del receptor de interleucina 23 y uso para tratar enfermedades inflamatorias | |
MX2020001774A (es) | Composiciones y métodos para tratar enfermedad colestásica. | |
MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
MX2022007989A (es) | Composiciones y metodos para tratar pterigion. | |
GB2541571A (en) | Pharmaceutical compositions | |
MX2016012574A (es) | Compuestos heteroarilo sustituidos y metodos de uso. | |
JOP20200035A1 (ar) | تركيبات حمض أميني لعلاج الإصابات العصبية | |
PH12017501990B1 (en) | Imidazopyrazinones as pde1 inhibitors | |
MD20160007A2 (ro) | Inhibitori ai RORC2 şi metode de utilizare a acestora | |
MX2018008645A (es) | Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano. | |
CO2017011778A2 (es) | Un inhibidor de la actividad del csf-1r y composiciones farmaceuticas que lo comprenden | |
NZ745187A (en) | 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | |
MX2022013283A (es) | Composiciones para limpieza de colon y tratamiento de trastornos gastrointestinales. | |
ZA202000558B (en) | Prevention and/or treatment of neurodegenerative disease | |
MX2016003293A (es) | Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados. | |
IL269400A (en) | Medicines and preparations for the treatment of eye disorders | |
MX2020008275A (es) | Metodos para tratar trastornos mitocondriales. | |
MX2020001256A (es) | Compuestos para la prevencion y el tratamiento de trastornos medicos y usos de los mismos. | |
MX2018007408A (es) | Uso de adyuvantes para la prevencion y/o el tratamiento de enfermedades autoinmunes. | |
PH12020551331A1 (en) | Treatment and prevention of pre-eclampsia | |
MX2017013879A (es) | Composiciones que comprenden anakinra. | |
PH12018502568A1 (en) | Composition comprising at least one enzyme and at least one microbicidal molecule for the prevention or treatment of post-implant infections |